Skip to main content
. 2020 Aug;23(8):1065–1077. doi: 10.22038/ijbms.2020.46654.10762

Table 1.

The dose of DOTAP, GP100 peptide and CpG adjuvant administered into the mouse with different formulations. Treatment groups were Peptide+CpG, Lip-peptide, and Lip-peptide+CpG

Treatment groups Formulation Particle Size (nm) PdI Zeta potential (mV)
Peptide + CpG GP100 + CpG 166.7 ± 5.42 0.287 ± 0.10 - 6.42 ± 0.00
Lip-peptide DOTAP: Chol: GP100 231.5 ± 3.04 0.315 ± 0.01 6.15 ± 3.09
Lip-peptide + CpG DOTAP: Chol: GP100 + CpG 277.7 ± 3.83 0.226 ± 0.06 -3.76 ± 6.14